About the Company
We do not have any company description for CURIS INC at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on CURIS INC
Curis to Release Third Quarter 2023 Financial Results and Hold ...
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 Oct. 26, 2023 8:30 AM ET Curis, Inc. (CRIS) ...
Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect
Curis Inc (NASDAQ:CRIS) is set to release its Q2 2025 earnings on Aug 5, 2025. The consensus estimate for Q2 2025 revenue is $2.64 million, and the earnings are expected to come in at -$1.36 per ...
Investors in Curis (NASDAQ:CRIS) have unfortunately lost 80% over the ...
This month, we saw the Curis, Inc. (NASDAQ:CRIS) up an impressive 44%. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Indeed, the share price is down a whopping 80 ...
Curis to Report Fourth Quarter 2024 Financial and ... - Morningstar
LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 ...
Curis Functional Health Named to Inc. 5000 List for Second Consecutive Year
Curis Functional Health is proud to be included on the Inc. 5000 list for the second consecutive year. Nicholas Marino Curis Functional Health +1 2143954269 email us here Visit us on social media: ...
The Hits Keep Coming With Curis's Secondary Offering
Curis stock traded up about 19% to $7.80, in a new 52-week range of $0.62 to $8.31. The consensus price target is $7.00.
CRIS | Curis Inc. Profile | MarketWatch
Company Profile Curis Inc. Building C 128 Spring Street Suite 500 Lexington, Massachusetts 02421 Phone1 617 503-6500 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 ...
Curis Provides First-Ever Demonstration that Targeting IRAK4 in ...
LEXINGTON, Mass., Dec. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ...
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination ...
LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ...
Why Curis, Inc. Is Soaring Today - Nasdaq
What happened Curis, Inc. (NASDAQ: CRIS) , a beaten up clinical-stage biopharma focused on cancer, jumped 23% as of 2:43 p.m. EDT on Thursday in.
Is Curis, Inc. (CRIS) Going to Burn These Hedge Funds?
Curis, Inc. (NASDAQ:CRIS) was in 6 hedge funds' portfolio at the end of the fourth quarter of 2012. CRIS has experienced a decrease in support from the world's most elite money managers recently.
Curis to Release First Quarter 2023 Financial Results and Hold ...
LEXINGTON, Mass., April 27, 2023 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that ...
Similar Companies
Loading the latest forecasts...